{"id":"maraviroc-celsentri","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Pyrexia"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Maraviroc is a selective antagonist of the CCR5 co-receptor, which HIV uses alongside CD4 to gain entry into host cells. By binding to CCR5 and blocking its interaction with HIV envelope proteins, the drug prevents viral attachment and fusion with the cell membrane. This mechanism is effective only against CCR5-tropic (R5) HIV strains, not X4-tropic variants.","oneSentence":"Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:08.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients with CCR5-tropic virus"},{"name":"HIV-1 infection in treatment-naïve patients with CCR5-tropic virus"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06511063","phase":"PHASE2","title":"Antiviral Clinical Trial for Long Covid-19","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2024-10-01","conditions":"Long Covid","enrollment":90},{"nctId":"NCT05470491","phase":"PHASE1, PHASE2","title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-26","conditions":"HIV, Hematologic Malignancies","enrollment":265},{"nctId":"NCT06853223","phase":"PHASE2","title":"This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-12-07","conditions":"Primary Graft Dysfunction, Lung Transplantation, Acute Lung Injury(ALI)","enrollment":120},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT02134717","phase":"NA","title":"Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes","status":"TERMINATED","sponsor":"Kevin F. Gibson","startDate":"2014-01","conditions":"Sarcoidosis","enrollment":3},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT07080567","phase":"PHASE2","title":"Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke","status":"RECRUITING","sponsor":"Emmanuel Carrera","startDate":"2025-07-14","conditions":"Ischemic Stroke, Stroke, Stroke Acute","enrollment":80},{"nctId":"NCT06805656","phase":"PHASE2","title":"Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals","status":"NOT_YET_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2025-09-01","conditions":"Hiv, HIV I Infection","enrollment":70},{"nctId":"NCT06640192","phase":"PHASE2","title":"Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir","status":"RECRUITING","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2025-05-30","conditions":"HIV-1-infection","enrollment":24},{"nctId":"NCT06974084","phase":"PHASE2, PHASE3","title":"Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).","status":"NOT_YET_RECRUITING","sponsor":"HealthBio, Inc.","startDate":"2025-09-01","conditions":"Long COVID","enrollment":252},{"nctId":"NCT01400412","phase":"PHASE2","title":"Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-01-17","conditions":"HIV-1 Infection","enrollment":262},{"nctId":"NCT04789616","phase":"PHASE2","title":"The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2022-09-15","conditions":"Stroke","enrollment":120},{"nctId":"NCT02881762","phase":"PHASE4","title":"Maraviroc Efficacy for Hepatitis C","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2017-06-01","conditions":"Hepatitis C, Human Immunodeficiency Virus","enrollment":10},{"nctId":"NCT04435522","phase":"PHASE1","title":"Maraviroc in Patients With Moderate and Severe COVID-19","status":"COMPLETED","sponsor":"Rhode Island Hospital","startDate":"2020-10-01","conditions":"COVID","enrollment":9},{"nctId":"NCT04721301","phase":"PHASE1","title":"Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial","status":"COMPLETED","sponsor":"University Hospital Heidelberg","startDate":"2017-01-15","conditions":"Colorectal Cancer Metastatic, Pancreatic Cancer Metastatic","enrollment":50},{"nctId":"NCT03178084","phase":"PHASE3","title":"Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2014-10-15","conditions":"HIV/AIDS","enrollment":721},{"nctId":"NCT02741323","phase":"PHASE2","title":"Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01-01","conditions":"HIV Infections, Kidney Diseases","enrollment":97},{"nctId":"NCT05932550","phase":"PHASE2","title":"Safety of Maraviroc for Post-stroke Depression","status":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2020-08-04","conditions":"Post-stroke Depression","enrollment":10},{"nctId":"NCT02475915","phase":"PHASE1, PHASE2","title":"Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection","status":"COMPLETED","sponsor":"SEARCH Research Foundation","startDate":"2015-01","conditions":"Acute HIV Infection","enrollment":15},{"nctId":"NCT04710199","phase":"PHASE2","title":"Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2021-02-23","conditions":"Virus Diseases","enrollment":44},{"nctId":"NCT01204905","phase":"NA","title":"R5 Integrase Study in HIV-1 Naive Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-09","conditions":"HIV Infections","enrollment":7},{"nctId":"NCT00665561","phase":"","title":"Prospective Observational Epidemiologic Study of Maraviroc's Safety","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2008-03-31","conditions":"Human Immunodeficiency Virus","enrollment":2500},{"nctId":"NCT03274804","phase":"PHASE1","title":"Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC","status":"COMPLETED","sponsor":"University Hospital Heidelberg","startDate":"2018-04-01","conditions":"Metastatic Colorectal Cancer, MSS","enrollment":20},{"nctId":"NCT04475991","phase":"PHASE2","title":"Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults","status":"TERMINATED","sponsor":"Hospital General de México Dr. Eduardo Liceaga","startDate":"2021-07-13","conditions":"COVID-19","enrollment":19},{"nctId":"NCT00948753","phase":"PHASE1, PHASE2","title":"Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2009-06","conditions":"Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation","enrollment":38},{"nctId":"NCT02519777","phase":"PHASE4","title":"Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04-21","conditions":"HIV Infections","enrollment":191},{"nctId":"NCT04441385","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).","status":"TERMINATED","sponsor":"Hospital Universitario Infanta Leonor","startDate":"2020-06-26","conditions":"COVID-19","enrollment":60},{"nctId":"NCT02778204","phase":"PHASE1","title":"Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-05","conditions":"HIV Infections","enrollment":47},{"nctId":"NCT01505114","phase":"PHASE2","title":"Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-06","conditions":"HIV Infection","enrollment":594},{"nctId":"NCT03129113","phase":"PHASE2, PHASE3","title":"Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV","status":"COMPLETED","sponsor":"University College, London","startDate":"2017-03-01","conditions":"Hepatic Steatosis, HIV-1-infection","enrollment":90},{"nctId":"NCT00537394","phase":"PHASE3","title":"Optimizing Treatment for Treatment-Experienced, HIV-Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-01","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT01896921","phase":"PHASE3","title":"Switch to Maraviroc + Integrase Inhibitor","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2013-09","conditions":"HIV","enrollment":7},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT02159027","phase":"PHASE2, PHASE3","title":"Maraviroc and NeuroAIDS Pathogenesis","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2015-06","conditions":"AIDS Dementia Complex","enrollment":48},{"nctId":"NCT03172026","phase":"PHASE2, PHASE3","title":"Maraviroc to Augment Rehabilitation Outcomes After Stroke","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2019-08-01","conditions":"Stroke","enrollment":2},{"nctId":"NCT04965662","phase":"PHASE4","title":"The Role of Home Packs of HIV PEPSE in High Risk Individuals","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2018-01-01","conditions":"HIV-1-infection","enrollment":139},{"nctId":"NCT04966429","phase":"PHASE2","title":"Safety and Efficacy of Maraviroc in Post-stroke Cognitive Impairment","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2021-05-01","conditions":"Post Stroke Cognitive Impairment","enrollment":150},{"nctId":"NCT03060447","phase":"PHASE1","title":"Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-05-09","conditions":"HIV-1 Infection","enrollment":25},{"nctId":"NCT01276236","phase":"PHASE2","title":"Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2011-03-09","conditions":"Kaposi's Sarcoma","enrollment":13},{"nctId":"NCT01785810","phase":"PHASE2","title":"Phase II Maraviroc for GVHD Prevention","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2013-02","conditions":"Hematologic Malignancy","enrollment":37},{"nctId":"NCT03163277","phase":"PHASE4","title":"Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)","status":"TERMINATED","sponsor":"Giovanni Di Perri","startDate":"2017-05-15","conditions":"Hiv, Neurocognitive Dysfunction","enrollment":38},{"nctId":"NCT03708861","phase":"PHASE3","title":"Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients","status":"WITHDRAWN","sponsor":"University of Turin, Italy","startDate":"2016-01","conditions":"HIV Infection","enrollment":""},{"nctId":"NCT01068873","phase":"PHASE4","title":"Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)","status":"TERMINATED","sponsor":"Temple University","startDate":"2010-04","conditions":"HIV Infections","enrollment":1},{"nctId":"NCT00925756","phase":"PHASE4","title":"CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-10-20","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT00735072","phase":"PHASE4","title":"Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-09","conditions":"HIV Infection","enrollment":45},{"nctId":"NCT02961829","phase":"NA","title":"Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2015-07","conditions":"Chronic Infection, HIV","enrollment":30},{"nctId":"NCT00791700","phase":"PHASE2","title":"An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children","status":"UNKNOWN","sponsor":"ViiV Healthcare","startDate":"2009-04-22","conditions":"Human Immunodeficiency Virus","enrollment":103},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02167451","phase":"PHASE1, PHASE2","title":"Maraviroc as GVHD Prophylaxis in Transplant Recipients","status":"TERMINATED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-07","conditions":"Diagnoses That Require Stem Cell Transplant, Graft Versus Host Disease (GVHD)","enrollment":31},{"nctId":"NCT01894776","phase":"PHASE1","title":"A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2013-06","conditions":"HIV Infection, HIV-1 Infection, Mycobacterium Avium Complex (MAC)","enrollment":15},{"nctId":"NCT02858401","phase":"PHASE1","title":"Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-29","conditions":"HIV-1 Infection","enrollment":48},{"nctId":"NCT00808002","phase":"PHASE3","title":"Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-02","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00864474","phase":"","title":"Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-03-31","conditions":"CCR5-tropic HIV-1 Infection","enrollment":68},{"nctId":"NCT02990312","phase":"PHASE4","title":"Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2017-05-01","conditions":"Hiv, Kidney Transplant, HIV Reservoir","enrollment":""},{"nctId":"NCT03218592","phase":"PHASE4","title":"ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-06-28","conditions":"HIV/AIDS","enrollment":36},{"nctId":"NCT01378910","phase":"PHASE4","title":"Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2011-06","conditions":"HIV","enrollment":74},{"nctId":"NCT00982878","phase":"PHASE1","title":"The Maraviroc Central Nervous System (CNS) Study","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2009-09","conditions":"HIV Infections","enrollment":13},{"nctId":"NCT01348763","phase":"PHASE1","title":"The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-10","conditions":"HIV","enrollment":13},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01367236","phase":"PHASE4","title":"Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-01","conditions":"HIV, Impaired Cognition","enrollment":60},{"nctId":"NCT00981773","phase":"PHASE4","title":"The St. Marys and The Mater Switch Study","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2009-09","conditions":"HIV Infections","enrollment":18},{"nctId":"NCT00908544","phase":"NA","title":"New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients","status":"COMPLETED","sponsor":"MUC Research GmbH","startDate":"2009-05-15","conditions":"HIV Infections","enrollment":47},{"nctId":"NCT03969550","phase":"","title":"Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2008-01","conditions":"AIDS, Progressive Multifocal Leucoencephalopathy (PML)","enrollment":34},{"nctId":"NCT01449006","phase":"PHASE4","title":"A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)","status":"COMPLETED","sponsor":"Bruce Brew","startDate":"2011-10","conditions":"Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND)","enrollment":19},{"nctId":"NCT00496782","phase":"PHASE1","title":"Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2007-07","conditions":"HIV Infections","enrollment":16},{"nctId":"NCT02208037","phase":"PHASE2","title":"Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2014-08","conditions":"Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia","enrollment":279},{"nctId":"NCT03118661","phase":"PHASE1","title":"Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2018-03-19","conditions":"HIV-1-infection","enrollment":""},{"nctId":"NCT00709111","phase":"NA","title":"Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-01","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00992654","phase":"","title":"A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India","status":"NO_LONGER_AVAILABLE","sponsor":"ViiV Healthcare","startDate":"","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":""},{"nctId":"NCT01627717","phase":"PHASE1","title":"The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2012-06","conditions":"Healthy","enrollment":11},{"nctId":"NCT03402815","phase":"PHASE4","title":"Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.","status":"COMPLETED","sponsor":"University Of Perugia","startDate":"2015-01-01","conditions":"HIV Infection With Other Conditions, Cardiovascular Risk Factor, Atherosclerosis","enrollment":22},{"nctId":"NCT02333045","phase":"NA","title":"Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women","status":"TERMINATED","sponsor":"Emory University","startDate":"2015-01","conditions":"HIV","enrollment":4},{"nctId":"NCT02641444","phase":"","title":"Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2016-04-13","conditions":"HIV","enrollment":5},{"nctId":"NCT01327547","phase":"PHASE4","title":"A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-05-18","conditions":"HIV Coinfection","enrollment":138},{"nctId":"NCT02480894","phase":"PHASE1","title":"A Open-label, Drug-Drug Interaction With Maraviroc (DDI)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-07-07","conditions":"Infection, Human Immunodeficiency Virus","enrollment":112},{"nctId":"NCT02346084","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults","status":"COMPLETED","sponsor":"International Partnership for Microbicides, Inc.","startDate":"2015-01","conditions":"HIV/AIDS","enrollment":19},{"nctId":"NCT00870363","phase":"PHASE4","title":"A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2009-04","conditions":"HIV Infections","enrollment":44},{"nctId":"NCT01076179","phase":"","title":"Kaletra in Combination With Antiretroviral Agents","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-09","conditions":"Human Immunodeficiency Virus","enrollment":502},{"nctId":"NCT00935480","phase":"PHASE3","title":"IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2010-10","conditions":"HIV Infections","enrollment":17},{"nctId":"NCT02625207","phase":"PHASE1","title":"THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-11-06","conditions":"Healthy Subjects","enrollment":47},{"nctId":"NCT01776996","phase":"","title":"An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc","status":"NO_LONGER_AVAILABLE","sponsor":"ViiV Healthcare","startDate":"","conditions":"Infection, Human Immunodeficiency Virus","enrollment":""},{"nctId":"NCT00987948","phase":"PHASE2","title":"Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2010-01","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT01736813","phase":"","title":"CCR5-blockade in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"National Center for Tumor Diseases, Heidelberg","startDate":"2012-11","conditions":"Colorectal Cancer, Neoplasm Metastasis, Liver Metastases","enrollment":12},{"nctId":"NCT02934022","phase":"NA","title":"Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients","status":"COMPLETED","sponsor":"Southern California Institute for Research and Education","startDate":"2012-06","conditions":"HIV Infection","enrollment":25},{"nctId":"NCT02588820","phase":"PHASE3","title":"Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection","status":"UNKNOWN","sponsor":"David Garcia Cinca","startDate":"2016-04","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT01348308","phase":"PHASE3","title":"Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-09","conditions":"HIV-1 Infection, AIDS","enrollment":407},{"nctId":"NCT00426660","phase":"PHASE3","title":"Expanded Access Program for Maraviroc At Multiple Centers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2007-02","conditions":"HIV Infections","enrollment":1047},{"nctId":"NCT02799888","phase":"PHASE2","title":"Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2014-04","conditions":"Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation","enrollment":40},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT00719823","phase":"PHASE3","title":"Maraviroc Compassionate Use","status":"WITHDRAWN","sponsor":"ViiV Healthcare","startDate":"2008-08","conditions":"Human Immunodeficiency Virus Type 1","enrollment":""},{"nctId":"NCT01154673","phase":"PHASE2, PHASE3","title":"Effects of Intensive cART During Acute/Early HIV Infection","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2011-11","conditions":"Acute HIV Infection","enrollment":32},{"nctId":"NCT01680536","phase":"PHASE4","title":"A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2012-11","conditions":"HIV","enrollment":19},{"nctId":"NCT01367210","phase":"PHASE4","title":"Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)","status":"TERMINATED","sponsor":"Catholic University of the Sacred Heart","startDate":"2011-06","conditions":"HIV Infection","enrollment":165},{"nctId":"NCT00764465","phase":"PHASE2","title":"An Interaction Study to Assess Drug Levels in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Garden State Infectious Disease Associates, PA","startDate":"2008-10","conditions":"Healthy","enrollment":45},{"nctId":"NCT01585753","phase":"","title":"MARCH Vascular Endothelium Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Cardiovascular Disease","enrollment":34},{"nctId":"NCT01637233","phase":"","title":"MARCH Central Nervous System Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"HIV-1 Infection","enrollment":28},{"nctId":"NCT01384682","phase":"PHASE4","title":"Maraviroc Switch Collaborative Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2011-08","conditions":"HIV","enrollment":399},{"nctId":"NCT01637259","phase":"PHASE4","title":"MARCH Renal Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Proteinuria, HIV","enrollment":76}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Maraviroc (Celsentri)","genericName":"Maraviroc (Celsentri)","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells. Used for HIV-1 infection in treatment-experienced patients with CCR5-tropic virus, HIV-1 infection in treatment-naïve patients with CCR5-tropic virus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}